Manus

Manus is a biotechnology company that specializes in synthetic biology and industrial biomanufacturing. The company has developed a proprietary platform called the BioOptimization Cycle, which integrates cell factory design, enzyme engineering, and precision fermentation to produce complex molecules. By engineering bacterial and yeast species as "cell factories," Manus creates bioalternatives—chemically identical replacements for ingredients traditionally sourced from plants, animals, or petrochemicals. These engineered microbes are designed for higher productivity and scalability, allowing the company to bridge the transition from laboratory-scale discovery to large-scale commercial manufacturing. Manus operates research, development, and production facilities across the United States, Singapore, and Peru to support its end-to-end biomanufacturing capabilities.

The company partners with various industries, including food, beverage, and pharmaceuticals, to help them replace conventional ingredients with sustainable, high-performance bioalternatives, thereby improving supply chain resilience and reducing environmental impact. Through programs like the BioAccelerator and BioManufacturing initiatives, Manus provides customized development services that help customers overcome the technical and capital constraints often encountered when scaling biotechnology processes. The company’s portfolio includes commercialized products such as bioalternatives for flavor and fragrance ingredients and various sweetener brands, supported by a significant intellectual property portfolio of over 200 patents. Manus also engages in public-private partnerships, including collaborations with government agencies, to advance domestic manufacturing of critical medicines and essential materials.